GeneCentric Begins Study to Validate RNA Gene Signature Test in Bladder Cancer
GeneCentric investigators will assess the ability of the FGFR predictive response signature to identify bladder cancer patients who may benefit from targeted therapy.
UMiami Researchers to Study Cell Therapy Response in Lymphoma Using WGS, Single-Cell RNA-seq
The team has received a $1.5 million US Department of Defense grant to help launch its project on diffuse B-cell lymphoma resistance to CAR T-cell therapy.
FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic for Takeda's Exkivity
Foundation Medicine said its assay is the only blood-based comprehensive genomic profiling platform to have gained this approval for Takeda's EGFR drug.
Personalis to Test MRD Assay in Triple-Negative Breast Cancer Trial With ABRCC, Criterium
The company has partnered with the Academic Breast Cancer Consortium and Criterium to assess its test in a prospective trial with five years of follow-up.
Tempus Gains FDA Premarket Approval for NGS Solid Tumor Profiling Test
The xT CDx is a 648-gene next-generation sequencing test that can help guide treatments for colorectal cancer patients with targeted therapies.